Navigation Links
Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
Date:3/31/2008

SHANGHAI, China, March 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech, the leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, was very honored to have Professor David W. C. MacMillan, a renowned researcher from Princeton University, as a WuXi PharmaTech Science Seminar Series speaker who delivered a lecture to the company's young scientists on March 25, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Aiming to keep the company's young scientists abreast of the latest drug R&D knowledge and technologies, the WuXi PharmaTech Science Seminar Series is a monthly program that invites accomplished researchers from academia and the industry to share their wealth of experience and expertise with the company's scientists.

Dr. David MacMillan obtained his undergraduate degree from Glasgow University, and in 1990 moved to the University of California, Irvine, where he obtained his Ph.D. under the direction of Larry E. Overman. Following postdoctoral research with David A. Evans at Harvard University, Dr. MacMillan began his independent research career at the University of California, Berkeley, in 1998. In 2000, he joined the department of chemistry at Caltech, and was promoted to full professor in 2003. He was appointed to the A. Barton Hepbum Chair of Chemistry and Director of the Merck Center for Catalysis at Princeton University in June 2006.

Dr. MacMillan is a leader in the currently active area of asymmetric organocatalysis. His numerous accomplishments have found widespread industrial application and his success is evidenced by the numerous awards and honors he has received from professional associations like the Royal Society of Chemistry, the American Chemical Society and the industry.

"We are very honored and privileged to have Dr. MacMillan as one of our seminar speakers. His remarkable achievements in the field of organic synthesis will motivate our young scientists," said Dr. Shuhui Chen, Chief Scientific Officer of the company. "As a research-driven company serving global pharmaceutical, biotechnology and medical device companies, we believe science has no boundary. We will continue inviting heavy-weight speakers to WuXi so that our scientists can learn from the best, and ultimately provide better services to our customers."

About WuXi PharmaTech

WuXi PharmaTech, headquartered in Shanghai, China, is a leading global pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the U.S. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies. Our services are designed to assist our global customers in shortening the time and lowering the cost of drug and medical device R&D by providing cost- effective and efficient outsourcing solutions. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Princeton scientists break choleras lines of communication
2. First look: Princeton researchers peek into deepest recesses of human brain
3. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
4. University of Iowa professor identifies new eating disorder
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
7. N.J. nurses are overworked according to Rutgers College of Nursing professor
8. Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award
9. Boston University School of Medicine Professor receives award from American Heart Association
10. Louisiana Tech professor is Small Times Innovator of the Year
11. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: